Each stage in the “immune response cycle” represents a therapeutic opportunity in immuno-oncology.
We refer to these as Therapeutic Nodes*. Key therapeutic nodes include the triggering of immunogenic cancer cell death, the activation of dendritic cells, the reversal of active immune suppression, and the direct stimulation of effector immune cells (such as T and NK cells). Arcus is building a wide portfolio of immune-focused cancer therapies that target one or more therapeutic nodes. This therapeutic portfolio will enable us to create, study and develop combination treatments that address the pathways of immune dysregulation most prevalent in particular malignancies or patient subgroups. Several drug discovery programs have already produced optimized compounds that are expected to advance into clinical development within the next 6-18 months. Several other programs are at earlier stages of drug optimization.